tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH), Arvinas Holding Company (ARVN) and Prestige Consumer Healthcare (PBH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lantheus (LNTHResearch Report), Arvinas Holding Company (ARVNResearch Report) and Prestige Consumer Healthcare (PBHResearch Report).

Lantheus (LNTH)

In a report released today, Justin Walsh from B.Riley Financial initiated coverage with a Buy rating on Lantheus and a price target of $91.00. The company’s shares closed last Friday at $64.20, close to its 52-week high of $69.74.

According to TipRanks.com, Walsh is ranked 0 out of 5 stars with an average return of -50.0% and a 7.7% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, Compass Therapeutics, and Vor Biopharma.

Lantheus has an analyst consensus of Strong Buy, with a price target consensus of $86.25, implying a 34.3% upside from current levels. In a report issued on May 2, Truist Financial also maintained a Buy rating on the stock with a $94.00 price target.

See the top stocks recommended by analysts >>

Arvinas Holding Company (ARVN)

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Arvinas Holding Company, with a price target of $64.00. The company’s shares closed last Friday at $45.68, close to its 52-week low of $44.96.

According to TipRanks.com, Flynn is a 4-star analyst with an average return of 13.3% and a 62.7% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Eli Lilly & Co.

Arvinas Holding Company has an analyst consensus of Strong Buy, with a price target consensus of $109.58, a 121.0% upside from current levels. In a report released today, Wedbush also downgraded the stock to Hold with a $43.00 price target.

Prestige Consumer Healthcare (PBH)

In a report released today, Linda Bolton Weiser from D.A. Davidson maintained a Hold rating on Prestige Consumer Healthcare, with a price target of $60.00. The company’s shares closed last Friday at $54.88.

According to TipRanks.com, Weiser is a 4-star analyst with an average return of 4.2% and a 49.3% success rate. Weiser covers the Consumer Goods sector, focusing on stocks such as The Estée Lauder Companies, Lifetime Brands, and 1-800 Flowers.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prestige Consumer Healthcare with a $59.33 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LNTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More